Stocks Health care MRK
NYSE · Health careMerck & Co., Inc. (MRK)
Merck & Co., Inc. brought in $66.6B of revenue over the twelve months to June 30, 2026, up 4.6% from a year earlier. Net income was $3.2B, a net margin of 4.8%. Operating cash flow minus capital spending left $12.4B of free cash flow in fiscal 2025. At June 30, 2026 it held $6.8B in cash against $51.1B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
Key facts about Merck & Co., Inc.
- Net worth
- Merck & Co., Inc. has a market value (market cap) of $358.9B at the latest share price, and shareholders' equity of $41.9B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $65B (+1.3% year on year), with net income of $18.3B. Over the 12 months to June 30, 2026: revenue $66.6B, net income $3.2B.
- Cash flow
- In fiscal 2025 operations brought in $16.5B of cash; after $4.1B of capital spending, free cash flow was $12.4B.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 7, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Merck & Co., Inc.'s next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
- Dividend
- Merck & Co., Inc. declared dividends of $3.28 per share in fiscal 2025, a yield of 2.26% at the current price.
What Merck & Co., Inc. does
Merck & Co. develops and manufactures prescription medicines, vaccines, and animal health products. The company sells its drugs to hospitals, pharmacies, and healthcare providers worldwide. It is known for producing cancer therapies, diabetes treatments, and vaccines for human and animal use. Its shares trade on NYSE under the ticker MRK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $65B | $18.3B | $7.28 | $12.4B |
| 2024 | $64.2B | $17.1B | $6.74 | $18.1B |
| 2023 | $60.1B | $365M | $0.14 | $9.1B |
| 2022 | $59.3B | $14.5B | $5.71 | $14.7B |
| 2021 | $48.7B | $13B | $5.14 | $8.7B |
| 2020 | $41.5B | $7.1B | $2.78 | $5.8B |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MRK ranks in Health care
Dividends
Merck & Co., Inc. declared $3.28 per share in fiscal 2025. At the current price that is a yield of 2.26%. It paid out $8.2B in cash dividends, 45% of its net income.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | $3.28 | $8.2B | 45% |
| 2024 | $3.12 | $7.8B | 46% |
| 2023 | $2.96 | $7.4B | 2,040% |
| 2022 | $2.80 | $7B | 48% |
| 2021 | $2.64 | $6.6B | 51% |
| 2020 | $2.48 | $6.2B | 88% |
Latest SEC filings
What Merck & Co., Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 5.1% to $16.6B versus the same quarter last year; diluted EPS -$0.54 versus $1.76.
- August 7, 2026Form 13F-HR filing 13F-HR
- August 4, 2026
- June 24, 2026
- June 24, 2026
- June 24, 2026
- May 29, 2026
- May 28, 2026
- May 22, 2026Other event 8-K
- May 13, 2026Form 13F-HR filing 13F-HR
What is MRK worth? A DCF from its reported cash flow
Insider trades
What the people running Merck & Co., Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $30M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 13, 2026 | Guindo ChirfiEVP, Access, Policy & Comms | Sold | 10,000 | $1.4M |
| August 12, 2026 | Zachary JenniferEVP, General Counsel | Exercised options | 41,494 | $4.9M |
| August 12, 2026 | Zachary JenniferEVP, General Counsel | Exercised options | 13,433 | $1.1M |
| August 12, 2026 | Zachary JenniferEVP, General Counsel | Sold | 80,315 | $10.7M |
| August 12, 2026 | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sold | 11,099 | $1.5M |
| August 12, 2026 | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sold | 600 | $79.2K |
| August 11, 2026 | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sold | 7,410 | $973.2K |
| August 11, 2026 | DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sold | 5,427 | $718.3K |
Who owns MRK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Merck & Co., Inc.13G, passive with 2 related filers | 19.96% | February 3, 2025 |
| Vanguard Capital Management13G, passive | 7.53% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 3,824 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 226,999,837 | +1,169,507 |
| Vanguard Capital Management LLC | 161,323,174 | +335,550 |
| State Street Corp | 120,413,256 | +1,087,583 |
| Wellington Management Group Llp | 86,249,283 | +1,934,312 |
| Vanguard Portfolio Management LLC | 67,738,969 | +434,664 |
| Geode Capital Management, LLC | 60,744,214 | +1,186,060 |
| Charles Schwab Investment Management Inc | 54,365,289 | +4,600,064 |
| Morgan Stanley | 48,641,158 | +1,008,671 |
| Fmr LLC | 45,440,355 | +924,345 |
| Jpmorgan Chase & Co | 43,886,420 | -9,086,563 |
| Fisher Asset Management, LLC | 38,516,263 | +12,079,979 |
| Norges Bank | 36,983,784 | new |
| Bank of America Corp | 30,535,208 | -239,013 |
| Northern Trust Corp | 26,275,718 | -814,305 |
| Goldman Sachs Group Inc | 22,075,139 | +1,941,760 |
| Franklin Resources Inc | 19,548,585 | +3,281,380 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 19,547,171 | -867,648 |
| Legal & General Group Plc | 18,873,343 | -665,202 |
| Invesco Ltd. | 18,611,171 | -3,243,930 |
| Bank of New York Mellon Corp | 18,340,173 | -373,190 |
Insiders
13 insiders reported holding 968,444 shares in total, about $140.9M at the last price.
| Holder | Shares |
|---|---|
| Davis Robert MChairman, CEO & President, Director | 450,351 |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | 110,167 |
| Li Dean YExecutive VP & President, MRL | 94,431 |
| Litchfield CarolineEVP & CFO | 92,301 |
| Zachary JenniferEVP, General Counsel | 45,509 |
| Guindo ChirfiEVP, Access, Policy & Comms | 36,613 |
| Williams David MichaelEVP,Chief Info&Digital Officer | 31,716 |
| Romanelli JosephPresident, Human Health Int?l | 28,739 |
| Oosthuizen Johannes JacobusEVP, Oncology & Int?l | 21,895 |
| Maraldo David R.EVP & Pres. MMD | 18,212 |
Questions about MRK
What does Merck & Co., Inc. do?
Merck & Co. develops and manufactures prescription medicines, vaccines, and animal health products. The company sells its drugs to hospitals, pharmacies, and healthcare providers worldwide. It is known for producing cancer therapies, diabetes treatments, and vaccines for human and animal use. Its shares trade on NYSE under the ticker MRK.
What is Merck & Co., Inc.'s net worth?
Merck & Co., Inc. has a market value (market cap) of $358.9B at the latest share price, and shareholders' equity of $41.9B on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Merck & Co., Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $3.2B on revenue of $66.6B, a net margin of 4.8%.
How much revenue does Merck & Co., Inc. make?
Over the twelve months to June 30, 2026 Merck & Co., Inc. reported revenue of $66.6B. That is 4.6% more than a year earlier.
When did Merck & Co., Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 1, 2026.
When is Merck & Co., Inc.'s next earnings report?
Merck & Co., Inc.'s next report is expected around October 29, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Does Merck & Co., Inc. pay a dividend?
Yes. Merck & Co., Inc. declared dividends of $3.28 per share in fiscal 2025, a yield of 2.26% at the current price.
Similar companies
Compare MRK with
Follow MRK
Get an email when Merck & Co., Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Merck & Co., Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.